NCT06068738

Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer

Observational Analysis of the Association of Drug Activity Measured in Viable Tumour Tissues ex Vivo and Clinical Response in Ovarian Cancer: A Basic Research Study

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 13 (actual)
• Sponsor: Exscientia AI Limited · Industry
• Sex: Female
• Age: 18 Years – 125 Years
• Healthy volunteers: Not accepted

Summary

EXCYTE-1 is a multicentre, prospective observational study to investigate the relationship between ex vivo drug response (EVDR), measured in ovarian tumour-derived samples using high content imaging, and actual patient clinical response. Patients with newly diagnosed or relapsed/refractory epithelial ovarian carcinoma, that present with malignant effusions (ascites or pleural effusions), will be enrolled in the study before starting their initial or next treatment line. Enrolled patients will be asked to provide ascites, peripheral blood and fresh tumour tissue if available. Samples will be shipped to the sponsor laboratory and their response to standard of care drugs evaluated ex vivo. Participants will: * provide samples during routine clinical procedures * agree that data about their medical history, diagnosis and health status at the following timepoints are collected: at signature of the consent form, at the time samples are provided, at start of the therapy, upon completion of the therapy, regularly after completion of the therapy

Conditions

• Epithelial Ovarian Cancer

Interventions

Type	Name	Description
OTHER	Biological sample collection	Collection of ascites, blood and fresh tumour tissues (if available)

Timeline

• Start date: 2023-04-14
• Primary completion: 2024-08-14
• Completion: 2024-08-14
• First posted: 2023-10-05
• Last updated: 2024-09-26

Locations

4 sites across 2 countries: Austria, Germany